With the deal, Imugene will be able to save $32 million and extend its cash runway through 2026 due to the outsourcing and staff cuts.
Kincell Bio to acquire Imugene's North Carolina manufacturing facility for up to $6M USD in upfront and milestone-driven payments over three yearsKincell will expand its capacity and commitment to...
Imugene opened enrollment for its CF-33 (VAXINIA) expansion study in bile tract cancer (cholangiocarcinoma) patients.
Imugene announced poster presentations featuring its CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx at the AACR Conference.
Phase 1 onCARlytics solid tumour trial advances to combination arm treatment
Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, highlighted recent progress across the company's immuno-oncology portfolio.
SYDNEY, AUSTRALIA / ACCESSWIRE / January 18, 2024 / Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to announce further details from its poster presentation at the ASCO Gastrointestinal Cancers Symposium (ASCO-GI) currently being conducted in San Francisco.
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
The US Food and Drug Administration (FDA) has granted clearance to Imugene’s investigational new drug (IND) application for initiating a Phase I clinical trial of onCARlytics (on-CAR-19, CF33-CD19, HOV4), its oncolytic virotherapy candidate, to treat advanced or metastatic solid tumours.